Abstracts tagged "rheumatoid arthritis"

Abstract Number: 0921 • ACR Convergence 2022
Effects of Methotrexate on the Liver Function and Disease Activity of Newly Diagnosed RA Patients Depending on the Cardiometabolic Profile
Ivan Arias-de la Rosa¹, Miriam Ruiz-Ponce¹, Laura Cuesta-Lopez¹, Rafaela Ortega-Castro¹, Jerusalem Calvo¹, lourdes Ladehesa-Pineda², Carlos Pérez-Sánchez¹, Chary López-Pedrera³, Eduardo Collantes¹, Alejandro Escudero-Contreras¹ and Nuria Barbarroja¹, ¹IMIBIC/University of Cordoba/Reina Sofia Hospital, Cordoba, Spain, ²Reina Sofia University Hospital/Rheumatology Department/Maimonides Institute for Biomedical Research (IMIBIC), Cordoba, Spain, ³Maimonides Institute for Biomedical Research of Córdoba, Cordoba, Spain
Background/Purpose: Methotrexate (MTX) is the first-line treatment in Rheumatoid arthritis (RA) patients. To date, the evidence about the liver disease caused by MTX is controversial.…
Abstract Number: 0938 • ACR Convergence 2022
Baseline Predictors of Disease Flare upon csDMARD Withdrawal in Patients with Rheumatoid Arthritis in Sustained Remission After DAS-driven Therapy: Role of the Systemic Autoimmune Status and Peripheral Joint Ultrasound Across a 5-year Follow-up
Antonio Manzo¹, Emanuele Bozzalla Cassione², Iolanda Mazzucchelli³, Silvia Grignaschi³, Blerina Xoxi³, Terenzj Luvaro³, Ludovico De Stefano³, Garifallia Sakellariou³, SERENA BUGATTI³ and Carlomaurizio Montecucco⁴, ¹IRCCS Policlinico San Matteo Foundation/University of Pavia, Pavia, Pavia, Italy, ²University of Pavia, IRCCS Policlinico San Matteo Foundation, Milano, Milan, Italy, ³University of Pavia, IRCCS Policlinico San Matteo Foundation, Pavia, Italy, Pavia, Italy, ⁴Department of Rheumatology, IRCCS Policlinico S. Matteo Foundation, University of Pavia, Pavia, Italy
Background/Purpose: Early diagnosis and treat-to-target strategies with synthetic conventional DMARDs in rheumatoid arthritis (RA) have allowed the achievement of remission in a significant percentage of…
Abstract Number: 1152 • ACR Convergence 2022
A Novel Serological Biomarker Measuring a Fragment of Cartilage Intermediate Layer Protein 1 Is Highly Upregulated in Rheumatic Diseases
Helena Port¹, Walter P Maksymowych², Morten Karsdal³, Anne-Christine Bay-Jensen³ and Signe Holm Nielsen³, ¹University of Copenhagen, Copenhagen, Denmark, ²Department of Medicine, University of Alberta, Edmonton, AB, Canada, ³Nordic Bioscience, Herlev, Denmark
Background/Purpose: A hallmark of rheumatic joint diseases is altered cartilage protein turnover and protein composition. During cartilage erosions, the cartilage intermediate layer protein-1 (CILP-1), is…
Abstract Number: 1266 • ACR Convergence 2022
Time-course Ultrasonography to Predict Flare After Discontinuation of Biologics in Patients with Rheumatoid Arthritis Achieving Stringent Remission
Takehisa Ogura¹, Takaharu Katagiri², Yuto Takakura³, Chihiro Imaizumi⁴ and Hideto Kameda⁴, ¹Toho university, Meguro-ku, Japan, ²Toho University School of Medicine (Ohashi Medical Center), Division of Rheumatology, Department of Internal Medicine, Tokyo, Japan, ³Toho University, Setagayaku, Japan, ⁴Toho University, Tokyo, Japan
Background/Purpose: Ultrasonography (US) has been suggested to be useful in predicting flare in patients with rheumatoid arthritis (RA) after discontinuation of biological disease-modifying antirheumatic drugs…
Abstract Number: 1389 • ACR Convergence 2022
The New Serum Synovial Biochemical Marker HELIX-III Predicts Radiological Progression in Early Arthritis Independently of Usual Risk Factors
Patrick Garnero¹, Evelyne Gineyts¹, Jean-Charles Rousseau¹, Pascal Richette², Jérémie SELLAM³ and Roland Chapurlat¹, ¹INSERM 1033, Lyon, France, ²Department of Rheumatology, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris, France, ³Sorbonne Universite, AP-HP, Saint-Antoine hospital, Paris, France
Background/Purpose: The prognosis of rheumatoid arthritis (RA) is highly variable across patients (P.) and difficult to predict. Usual risk factors, e.g., radiological joint damage, increased…
Abstract Number: 1405 • ACR Convergence 2022
In Contrast to Anti-CCP, Then MMP Degraded and Citrullinated Vimentin (VICM) Is Both a Diagnostic and Treatment Response Biomarker
Patryk Drobinski¹, Neel I. Nissen¹, morten A. Karsdal², Nicholas Willumsen² and Anne-Christine Bay-Jensen², ¹University of Copenhagen, Copenhagen, Denmark, ²Nordic Bioscience, Herlev, Denmark
Background/Purpose: The degree of protein citrullination and degradation by matrix metalloproteinases (MMP) play a central role in the pathology of rheumatoid arthritis (RA). Autoantibodies are…
Abstract Number: 1423 • ACR Convergence 2022
Long-Term Treatment with Golimumab Is a Safe Treatment Option Regardless of Risk Factors in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Axial Spondyloarthritis: Results from a Real-World Canadian Setting
Regan Arendse¹, Proton Rahman², Philip Baer³, Derek Haaland⁴, Dalton Sholter⁵, Odalis Asin-Milan⁶, Meagan Rachich⁷, Emmanouil Rampakakis⁸, A. Marilise Marrache⁹ and Allen J. Lehman¹⁰, ¹Community Rheumatology Care, Saskatoon, Canada, ²Memorial University, St. John's, NL, Canada, ³Baer Weinberg MPC, Scarborough, ON, Canada, ⁴The Waterside Clinic, Oro Medonte, ON, Canada, ⁵University of Alberta, Edmonton, AB, Canada, ⁶Janssen Canada, Laval, QC, Canada, ⁷Janssen Inc., Guelph, ON, Canada, ⁸McGill University, Department of Pediatrics and JSS Medical Research, Montréal, QC, Canada, ⁹Janssen Inc., Dollard-des-Ormeaux, QC, Canada, ¹⁰Janssen Inc., Toronto, ON, Canada
Background/Purpose: Golimumab (GLM), a tumor necrosis factor inhibitor (TNFi), has demonstrated efficacy and a favorable safety profile in inflammatory rheumatic diseases. Recent safety studies with…
Abstract Number: 1587 • ACR Convergence 2022
Efficacy and Safety of Curcumin in Maintaining Remission During Disease Modifying Anti Rheumatic Drug Withdrawal in Rheumatoid Arthritis at 52 Weeks: Phase III Double-Blind Randomized Placebo Controlled Trial
Padmanabha Shenoy¹, Sreeja Bhatt², Reshma Reji², Anuroopa Vijayan², Manju Mohanan², Sakir Ahmed³, Pankti Mehta⁴ and Aby Paul², ¹Centre for Arthritis and Rheumatism Excellence (CARE), Cochi, India, ²Centre for arthritis and Rheumatism excellence, Nettor, Kerala, Kochi, India, ³Kalinga Institute of Medical Sciences, Bhubaneswar, India, ⁴King George's Medical University, Lucknow, India
Background/Purpose: Curcumin, extracted from Curcuma (Turmeric) spices, has been shown to have anti-inflammatory properties in animal models of arthritis and in observational studies(1,2). Despite the…
Abstract Number: 1648 • ACR Convergence 2022
Risk of Vascular Events Under the Treatments with Janus Kinase Inhibitors in Patients with Rheumatoid Arthritis: An Analysis Using Japanese Health Insurance Database
Eiichi Tanaka¹, Ryoko Sakai², Eisuke Inoue³ and Masayoshi Harigai¹, ¹Division of Rheumatology, Department of Internal Medicine, Tokyo Women’s Medical University School of Medicine, Tokyo, Japan, ²Meiji Pharmaceutical University, Tokyo, Japan, ³Research Administration Center, Showa University, Shinagawa-ku, Japan
Background/Purpose: Janus kinase inhibitors (JAKIs) have shown positive therapeutic impacts on treatments for rheumatoid arthritis (RA), whereas, concerns have been raised about the risk of…
Abstract Number: 1746 • ACR Convergence 2022
Increased CD39+FoxP3+CD4+ Regulatory T Cells in Early Rheumatoid Arthritis Provide a Slot for Prompt Initiation of Methotrexate and Serve as Early Biomarkers of Clinical Response
María-Eugenia Miranda-Carús¹, Alejandro Villalba¹, Laura Nuño¹, Marta Benito-Miguel², Irene Monjo¹, Marta Novella-Navarro¹, Diana Peiteado¹, Sara Garcia-Carazo¹ and Alejandro Balsa³, ¹Hospital Universitario La Paz - IdiPAZ, Madrid, Spain, ²Universidad Nebrija, Physiology, Madrid, Spain, ³Hospital La Paz Institute for Health Research, Madrid, Spain
Background/Purpose: FoxP3+ regulatory CD4+ T cells (Tregs) are key to the homeostasis of the immune system. Stressed cells at inflammatory foci release adenine nucleotides to…
Abstract Number: 1835 • ACR Convergence 2022
Clinical Features of Patients with Sarcoidosis and Concomitant Connective Tissue Disease
Magdalena Harasimowicz¹, Emily GIlbert², Sarah Yi³ and Rochella Ostrowski⁴, ¹Loyola University Medical Center Department of Internal Medicine, Chicago, IL, ²Loyola University Medical Center Division of Pulmonary and Critical Care Medicine, Maywood, IL, ³Loyola University Stritch School of Medicine, Maywood, IL, ⁴Loyola University Medical Center Division of Rheumatology, Maywood, IL
Background/Purpose: Sarcoidosis is a multiorgan granulomatous disease with a prevalence of 60 per 100,000 in the United States.1 Given the low prevalence of both sarcoidosis…
Abstract Number: 1964 • ACR Convergence 2022
Systematic Screening of Multimorbidities Results in an Increased Intake of Comorbidity Preventive Medications and a Decreased Hospitalization Rate
Claire DAIEN¹, Vera Georgescu², Guillaume Decarriere³, Jenica Pastor³, Gaël Mouterde⁴, Cédric Lukas⁵, Grégoire Mercier³ and Jacques Morel⁶, ¹University Hospital, Saint-Gély-du-Fesc, France, ²Unité de Recherche Médico-économique, CHU de Montpellier et Université de Montpellier, Montpellier, France, ³CHU Montpellier, Montpellier, France, ⁴Lapeyronie Hospital, Montpellier, France, ⁵University Hospital Centre Montpellier, University of Montpellier, Montpellier, France, ⁶University and CHU Montpellier, Montpellier, France
Background/Purpose: A systematic screening of multimorbidities is performed since 2014 at the Montpellier University Hospital in patients with chronic inflammatory rheumatic diseases (IRD). The objective…
Abstract Number: 1982 • ACR Convergence 2022
Pluripotency Marker PBX1 Predicts Treatment Effect in Rheumatoid Arthritis
Karin Andersson¹, Eric Malmhäll-Bah², Nina Oparina¹, Tao Weiyang³, Malin Erlandsson¹, Venkataragavan Chandrasekaran², Aridaman Pandit³, Sofia Töyrä Silfverswärd⁴, Maria Bokarewa⁴ and Rille pullerits⁴, ¹Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Goteborg, Sweden, ²Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, ³Center for Translational Immunology, University Medical Center, Utrecht, Netherlands, ⁴Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Göteborg, Sweden
Background/Purpose: Self-renewal ability, which is important for the adaptive immunity and adequate T cell function, is severely impaired in rheumatoid arthritis (RA). This leads to…
Abstract Number: 1999 • ACR Convergence 2022
Patient-Reported Outcomes in Rheumatoid Arthritis Correlate with Clinical Disease Activity Index Response in the Study to Accelerate Information of Molecular Signatures (AIMS)
Vibeke Strand¹, Emelly Rusli², Lixia Zhang², Christina Le-Short², Alix Arnaud², Johanna Withers³ and Sam Asgarian², ¹Stanford University School of Medicine, Stanford, CA, ²Scipher Medicine Corporation, Waltham, MA, ³Scipher Medicine Corportaion, Waltham, MA
Background/Purpose: Rheumatoid arthritis (RA) treatment response is typically defined using clinician-reported scores and patient global assessments of disease activity (PtGA), but patients may have a…
Abstract Number: 2015 • ACR Convergence 2022
JAK Selectivity Did Not Affect to the Incidence of Malignancies in the Real-World Setting: Data from a Multicenter Observational Study in Japan
Tomohisa Uchida¹, Naoki Iwamoto², Shoichi Fukui², Fumiko Shomura³, Koichiro Aratake³, Toshiyuki Aramaki⁴, Yukitaka Ueki⁴ and Atsushi Kawakami², ¹Department of Rheumatology, National Hospital Organization Ureshino Medical Center, Department of Immunology and Rheumatology, Graduate School of Biomedical Sciences, Nagasaki University, Ureshino, Japan, ²Department of Immunology and Rheumatology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan, ³Department of Rheumatology, National Hospital Organization Ureshino Medical Center, Ureshino, Japan, ⁴Department of Rheumatology, Sasebo Chuo Hospital, Sasebo, Japan

Background/Purpose: Tofacitinib and baricitinib are the first and second approved JAK inhibitors for rheumatoid arthritis (RA) patients. Although their clinical efficacy has been well established,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].